Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

Daniel Keizman, David Sarid, Jae L. Lee, Avishay Sella, Maya Gottfried, Hans Hammers, Mario Eisenberger, Michael A Carducci, Victoria Sinibaldi, Victoria Neiman, Eli Rosenbaum, Avivit Peer, Avivit Neumann, Wilmosh Mermershtain, Keren Rouvinov, Raanan Berger, Ibrahim Yildiz

Research output: Contribution to journalArticle

Abstract

Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC. Methods. Records from mchRCC patients treated with first line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS),and overall survival (OS) between the groups. Results. Between 2004 and 2014, 36 patients (median age, 64 years; 47% male) with mchRCC were treated with first-line sunitinib. Seventy-eight percent achieved a clinical benefit (partial response 1 stable disease). Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the Heng risk (hazard ratio [HR], 3.3; p = .03) and pretreatment neutrophil-to-lymphocyte ratio (NLR) >3 (HR, 0.63; p = .02). Factors associated with OS were the Heng risk (HR, 4.1; p = .04), liver metastases (HR, 3.8; p = .03), and pretreatment NLR<3 (HR, 0.55; p =.03).Treatment outcome was not significantly different between mchRCC patients and individually matched mccRCC patients. In mccRCC patients (p value versus mchRCC),72% achieved a clinical benefit (p =.4) and median PFS and OS were 9 (p =.6) and 25 (p =.7)months, respectively. Conclusion. In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The Heng risk and pretreatment NLR may be associated with PFS and OS.

Original languageEnglish (US)
Pages (from-to)1212-1217
Number of pages6
JournalOncologist
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Survival
Neutrophils
Lymphocytes
Odds Ratio
sunitinib
Clear-cell metastatic renal cell carcinoma
Multivariate Analysis
Neoplasm Metastasis
Liver
Therapeutics

Keywords

  • Chromophobe type
  • Clear cell type
  • Metastatic renal cell carcinoma
  • Outcome
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Keizman, D., Sarid, D., Lee, J. L., Sella, A., Gottfried, M., Hammers, H., ... Yildiz, I. (2016). Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Oncologist, 21(10), 1212-1217. https://doi.org/10.1634/theoncologist.2015-0428

Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. / Keizman, Daniel; Sarid, David; Lee, Jae L.; Sella, Avishay; Gottfried, Maya; Hammers, Hans; Eisenberger, Mario; Carducci, Michael A; Sinibaldi, Victoria; Neiman, Victoria; Rosenbaum, Eli; Peer, Avivit; Neumann, Avivit; Mermershtain, Wilmosh; Rouvinov, Keren; Berger, Raanan; Yildiz, Ibrahim.

In: Oncologist, Vol. 21, No. 10, 01.10.2016, p. 1212-1217.

Research output: Contribution to journalArticle

Keizman, D, Sarid, D, Lee, JL, Sella, A, Gottfried, M, Hammers, H, Eisenberger, M, Carducci, MA, Sinibaldi, V, Neiman, V, Rosenbaum, E, Peer, A, Neumann, A, Mermershtain, W, Rouvinov, K, Berger, R & Yildiz, I 2016, 'Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib', Oncologist, vol. 21, no. 10, pp. 1212-1217. https://doi.org/10.1634/theoncologist.2015-0428
Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H et al. Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Oncologist. 2016 Oct 1;21(10):1212-1217. https://doi.org/10.1634/theoncologist.2015-0428
Keizman, Daniel ; Sarid, David ; Lee, Jae L. ; Sella, Avishay ; Gottfried, Maya ; Hammers, Hans ; Eisenberger, Mario ; Carducci, Michael A ; Sinibaldi, Victoria ; Neiman, Victoria ; Rosenbaum, Eli ; Peer, Avivit ; Neumann, Avivit ; Mermershtain, Wilmosh ; Rouvinov, Keren ; Berger, Raanan ; Yildiz, Ibrahim. / Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. In: Oncologist. 2016 ; Vol. 21, No. 10. pp. 1212-1217.
@article{d93a9f6c2b574f339c03e223f486da20,
title = "Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib",
abstract = "Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC. Methods. Records from mchRCC patients treated with first line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS),and overall survival (OS) between the groups. Results. Between 2004 and 2014, 36 patients (median age, 64 years; 47{\%} male) with mchRCC were treated with first-line sunitinib. Seventy-eight percent achieved a clinical benefit (partial response 1 stable disease). Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the Heng risk (hazard ratio [HR], 3.3; p = .03) and pretreatment neutrophil-to-lymphocyte ratio (NLR) >3 (HR, 0.63; p = .02). Factors associated with OS were the Heng risk (HR, 4.1; p = .04), liver metastases (HR, 3.8; p = .03), and pretreatment NLR<3 (HR, 0.55; p =.03).Treatment outcome was not significantly different between mchRCC patients and individually matched mccRCC patients. In mccRCC patients (p value versus mchRCC),72{\%} achieved a clinical benefit (p =.4) and median PFS and OS were 9 (p =.6) and 25 (p =.7)months, respectively. Conclusion. In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The Heng risk and pretreatment NLR may be associated with PFS and OS.",
keywords = "Chromophobe type, Clear cell type, Metastatic renal cell carcinoma, Outcome, Sunitinib",
author = "Daniel Keizman and David Sarid and Lee, {Jae L.} and Avishay Sella and Maya Gottfried and Hans Hammers and Mario Eisenberger and Carducci, {Michael A} and Victoria Sinibaldi and Victoria Neiman and Eli Rosenbaum and Avivit Peer and Avivit Neumann and Wilmosh Mermershtain and Keren Rouvinov and Raanan Berger and Ibrahim Yildiz",
year = "2016",
month = "10",
day = "1",
doi = "10.1634/theoncologist.2015-0428",
language = "English (US)",
volume = "21",
pages = "1212--1217",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

AU - Keizman, Daniel

AU - Sarid, David

AU - Lee, Jae L.

AU - Sella, Avishay

AU - Gottfried, Maya

AU - Hammers, Hans

AU - Eisenberger, Mario

AU - Carducci, Michael A

AU - Sinibaldi, Victoria

AU - Neiman, Victoria

AU - Rosenbaum, Eli

AU - Peer, Avivit

AU - Neumann, Avivit

AU - Mermershtain, Wilmosh

AU - Rouvinov, Keren

AU - Berger, Raanan

AU - Yildiz, Ibrahim

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC. Methods. Records from mchRCC patients treated with first line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS),and overall survival (OS) between the groups. Results. Between 2004 and 2014, 36 patients (median age, 64 years; 47% male) with mchRCC were treated with first-line sunitinib. Seventy-eight percent achieved a clinical benefit (partial response 1 stable disease). Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the Heng risk (hazard ratio [HR], 3.3; p = .03) and pretreatment neutrophil-to-lymphocyte ratio (NLR) >3 (HR, 0.63; p = .02). Factors associated with OS were the Heng risk (HR, 4.1; p = .04), liver metastases (HR, 3.8; p = .03), and pretreatment NLR<3 (HR, 0.55; p =.03).Treatment outcome was not significantly different between mchRCC patients and individually matched mccRCC patients. In mccRCC patients (p value versus mchRCC),72% achieved a clinical benefit (p =.4) and median PFS and OS were 9 (p =.6) and 25 (p =.7)months, respectively. Conclusion. In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The Heng risk and pretreatment NLR may be associated with PFS and OS.

AB - Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC. Methods. Records from mchRCC patients treated with first line sunitinib in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC patients were individually matched to mccRCC patients. We compared the clinical benefit rate, progression-free survival (PFS),and overall survival (OS) between the groups. Results. Between 2004 and 2014, 36 patients (median age, 64 years; 47% male) with mchRCC were treated with first-line sunitinib. Seventy-eight percent achieved a clinical benefit (partial response 1 stable disease). Median PFS and OS were 10 and 26 months, respectively. Factors associated with PFS were the Heng risk (hazard ratio [HR], 3.3; p = .03) and pretreatment neutrophil-to-lymphocyte ratio (NLR) >3 (HR, 0.63; p = .02). Factors associated with OS were the Heng risk (HR, 4.1; p = .04), liver metastases (HR, 3.8; p = .03), and pretreatment NLR<3 (HR, 0.55; p =.03).Treatment outcome was not significantly different between mchRCC patients and individually matched mccRCC patients. In mccRCC patients (p value versus mchRCC),72% achieved a clinical benefit (p =.4) and median PFS and OS were 9 (p =.6) and 25 (p =.7)months, respectively. Conclusion. In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The Heng risk and pretreatment NLR may be associated with PFS and OS.

KW - Chromophobe type

KW - Clear cell type

KW - Metastatic renal cell carcinoma

KW - Outcome

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84991695730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991695730&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0428

DO - 10.1634/theoncologist.2015-0428

M3 - Article

C2 - 27382030

AN - SCOPUS:84991695730

VL - 21

SP - 1212

EP - 1217

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -